TY  - JOUR
AU  - Korenkov, M.
AU  - Liebaert, J.
AU  - Yousefian, S.
AU  - Schwartz, Christian
AU  - Demel, U. M.
AU  - Braune, J.
AU  - Odabasi, M. C.
AU  - Herzberg, L.
AU  - Böckle, D.
AU  - Görür, N. C.
AU  - V Landenberg-Roberg, V.
AU  - Bohl, S.
AU  - Tregel, E.
AU  - Hennig, S.
AU  - Franke, C.
AU  - Haas, Simon
AU  - Keller, U.
AU  - Krönke, J.
AU  - Busse, Christian
TI  - Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.
JO  - Blood cancer journal
VL  - 15
IS  - 1
SN  - 2044-5385
CY  - [London]
PB  - Springer Nature
M1  - DKFZ-2025-02181
SP  - 168
PY  - 2025
AB  - Ciltacabtagene-autoleucel (cilta-cel) is a CAR-T cell therapy highly active in relapsed/refractory multiple myeloma but can induce severe immune-mediated toxicities. We describe two patients who developed chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel. Patient 1 presented with rapidly progressive gait ataxia, flaccid paraparesis, and oculomotor palsy 112 days post infusion; Patient 2 developed an analogous syndrome on day 19. In both patients, electromyography and nerve-conduction studies confirmed sensorimotor axonal-demyelinating neuropathy; brain MRI and CSF infection panels were unremarkable. CAR-T cells were detectable in blood and CSF, yet a predominance of CD8⁺ non-CAR-Tcells was observed. TCR-β sequencing revealed a hyper-expanded clone ( 30
KW  - Humans
KW  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: etiology
KW  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: diagnosis
KW  - Male
KW  - Middle Aged
KW  - Immunotherapy, Adoptive: adverse effects
KW  - Female
KW  - Aged
LB  - PUB:(DE-HGF)16
C6  - pmid:41115887
DO  - DOI:10.1038/s41408-025-01384-9
UR  - https://inrepo02.dkfz.de/record/305463
ER  -